Slow down disease progression

For some patients with advanced cholangiocarcinoma (bile duct cancer) with an IDH1 mutation who have already received previous treatments, TIBSOVO® has been shown to increase the length of time they can live without their disease getting worse.

Download Patient Brochure Download Icon

Why TIBSOVO?

Targeted Therapy

Targeted therapy

TIBSOVO targets the IDH1 mutation, a genetic mutation that occurs in about 20% of cholangiocarcinoma cases. Your doctor will order a biomarker test to determine if TIBSOVO is right for you.

Proven Results

Proven results

In the clinical trial, patients treated with TIBSOVO achieved longer progression-free survival and better disease control.a

Convenient Pills

Convenient once-daily pill

TIBSOVO is a once-daily pill you can take at home. As a targeted therapy, TIBSOVO works differently from traditional chemotherapy, which kills cells that divide quickly, including cells in healthy tissues.

a Progression-free survival is the length of time during and after cancer treatment that a patient lives with the disease without it getting worse. In a clinical trial, measuring the progression-free survival is one way to see how well treatment works. Disease control refers to the percentage of patients whose disease shrinks or remains stable over the study period.

Servier One

Patient support services

ServierONE offers patients helpful resources and tools for navigating treatment care, costs, and education throughout their journey.

Visit ServlerONE.com Arrow Icon or CALL 1-800-813-5905
Close button
 

What is TIBSOVO?

TIBSOVO is a prescription medicine used to treat adults with bile duct cancer (cholangiocarcinoma) that has spread:

  • who have already received previous treatment(s) and
  • whose tumor has a certain type of abnormal isocitrate dehydrogenase-1 (IDH1) mutation.

Your healthcare provider will perform a test to make sure that TIBSOVO is right for you. It is not known if TIBSOVO is safe and effective in children.

 

IMPORTANT SAFETY INFORMATION

TIBSOVO may cause serious side effects, including:

  • Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) during treatment with TIBSOVO. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint.
  • Guillain-Barr Syndrome. Guillain-Barr syndrome has happened in people treated with TIBSOVO. Your healthcare provider will monitor you for nervous system problems and will permanently stop your treatment with TIBSOVO if you develop Guillain-Barr syndrome. Tell your healthcare provider right away if you develop any signs or symptoms of Guillain-Barr syndrome, including:
  • weakness or tingling feeling in your legs, arms, or upper body
  • numbness and pain on one side or both sides of your body
  • any changes in your ability to see, touch, hear, or taste
  • burning or prickling sensation
  • difficulty breathing

The most common side effects of TIBSOVO in adults with Cholangiocarcinoma include:

  • fatigue
  • nausea
  • abdominal pain
  • diarrhea
  • cough
  • decreased appetite
  • fluid and swelling in your stomach area
  • vomiting
  • hemoglobin decreased (anemia)
  • rash
  • changes in liver function tests

Your healthcare provider will do blood tests before you start and during treatment with TIBSOVO. Your healthcare provider may decrease, temporarily hold, or permanently stop your treatment with TIBSOVO if you develop certain side effects.

TIBSOVO may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of TIBSOVO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking TIBSOVO, tell your healthcare provider about all of your medical conditions, including if you:

  • have any heart problems, including a condition called long QT syndrome.
  • have problems with abnormal electrolytes, such as sodium, potassium, calcium, or magnesium levels.
  • have nervous system problems.
  • have problems with your kidneys or are on dialysis.
  • have any liver disorders, including cirrhosis.
  • are pregnant or plan to become pregnant. TIBSOVO can cause harm to your unborn baby. You should avoid becoming pregnant during treatment with TIBSOVO. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with TIBSOVO.
  • are breastfeeding or plan to breastfeed. It is not known if TIBSOVO passes into your breast milk. Do not breastfeed during your treatment with TIBSOVO and for at least 1 month after your last dose of TIBSOVO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your doctor if you take hormonal contraceptives. TIBSOVO may affect how hormonal contraceptives work and may cause them to not work as well.

Please see Full Prescribing Information, including Medication Guide.

 

What is TIBSOVO?

TIBSOVO is a prescription medicine used to treat adults with bile duct cancer (cholangiocarcinoma) that has spread:

  • who have already received previous treatment(s) and
  • whose tumor has a certain type of abnormal isocitrate dehydrogenase-1 (IDH1) mutation.

IMPORTANT SAFETY INFORMATION

TIBSOVO may cause serious side effects, including:

  • Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) during treatment with TIBSOVO. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint.

IMPORTANT SAFETY INFORMATION